Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Immunotherapy is the use of medicines that help a person’s own immune system find and destroy cancer cells. It can be used to treat some people with liver cancer.
An important part of the immune system is its ability to keep itself from attacking normal cells in the body. To do this, it uses “checkpoints” – proteins on immune cells that need to be turned on (or off) to start an immune response. Cancer cells sometimes use these checkpoints to avoid being attacked by the immune system. Newer drugs that target these checkpoints hold a lot of promise as liver cancer treatments.
PD-1 is a checkpoint protein on immune cells called T cells. When PD-1 attaches to PD-L1, a protein on other cells in the body, it acts as a type of “off switch” that basically tells the T cell to leave the other cell alone. Some cancer cells have large amounts of PD-L1, which helps them hide from an immune attack. Drugs that target either PD-1 or PD-L1 can block this binding and boost the immune response against cancer cells.
Atezolizumab (Tecentriq) and durvalumab (Imfinzi) target the PD-L1 protein. Blocking this protein can help boost the immune response against cancer cells. This can shrink some tumors or slow their growth.
Atezolizumab can be used along with the targeted drug bevacizumab (Avastin) as the first treatment for liver cancer that cannot be treated by surgery or that has spread to other organs.
Durvalumab can be used with another immunotherapy drug tremelimumab (Imjudo) as the first treatment for liver cancer that cannot be removed with surgery.
These drugs are given as an infusion into a vein (IV), typically once every 2, 3, or 4 weeks.
Pembrolizumab (Keytruda) and nivolumab (Opdivo) are drugs that target PD-1, which can help boost the immune response against cancer cells. This can shrink some tumors or slow their growth.
These drugs can be used in people with advanced liver cancer who have previously been treated (such as with the targeted drug sorafenib [Nexavar]). Pembrolizumab can be used by itself, while nivolumab is typically used along with ipilimumab (see below).
These drugs are given as an intravenous (IV) infusion, typically every 2, 3, 4, or 6 weeks.
Ipilimumab (Yervoy) and tremelimumab (Imjudo) are other types of drugs that boost the immune response, but they have a different target. They block CTLA-4, another protein on T cells that normally helps keep them in check.
Tremelimumab (Imjudo) can be used with another immunotherapy drug durvalumab as the first treatment for liver cancer that cannot be removed with surgery. It is given as an intravenous (IV) infusion once every 4 weeks.
Ipilimumab can be used in combination with nivolumab to treat liver cancer that has previously been treated (such as with the targeted drug sorafenib). This drug is given as an intravenous (IV) infusion, usually once every 3 weeks for 4 treatments.
Side effects of these drugs can include:
Other, more serious side effects occur less often:
Infusion reactions: Some people might have an infusion reaction while getting these drugs. This is like an allergic reaction, and can include fever, chills, flushing of the face, rash, itchy skin, feeling dizzy, wheezing, and trouble breathing. It’s important to tell your doctor or nurse right away if you have any of these symptoms while getting these drugs.
Autoimmune reactions: These drugs work by basically removing one of the safeguards on the body’s immune system. Sometimes the immune system starts attacking other parts of the body, which can cause serious or even life-threatening problems in the lungs, intestines, liver, hormone-making glands, kidneys, skin, or other organs.
Serious side effects seem to occur more often with ipilimumab than with the PD-1 and PD-L1 inhibitors.
It’s very important to report any new side effects to your health care team promptly. If serious side effects do occur, treatment may need to be stopped and you may get high doses of corticosteroids to suppress your immune system.
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Fong Y, Dupey DE, Feng M, Abou-Alfa G. Ch. 57 - Cancer of the Liver. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2019:844-864.
National Cancer Institute. Physician Data Query (PDQ). Adult Primary Liver Cancer Treatment. Accessed at https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq on March 11, 2019.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. V.3.2020. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf on June 10, 2020.
Stuart KE. Systemic treatment for advanced hepatocellular carcinoma. UpToDate website. https://www.uptodate.com/contents/systemic-treatment-for-advanced-hepatocellular-carcinoma. Updated January 16, 2019. Accessed March 11, 2019.
Zhu AX, Finn RS, Edeline J, Cattan S et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
Last Revised: October 24, 2022
Donate now so we can continue to provide access to critical cancer information, resources, and support to improve lives of people with cancer and their families.